Introduction: Patients with primary adrenal insufficiency receive long - term glucocorticoid replacement therapy, which may cause osteoporosis.

AIM OF THE STUDY The aim of the study was to assess the effect of glucocorticoid replacement therapy in patients with Addison´s disease on bone mineral density (BMD), parameters of calcium - phosphate (Ca-P) metabolism as well as on bone turneover markers. PATIENTS AND METHODS The study group consisted of 46 patients with Addison´s disease (12men, 17 pre- and 17 postmenopausal women, the control group consisted of 44 healthy individuals (8 men, 16 prepre- and 16 postmenopausal women). Ca-P metabolism parameters, bone turnover markers and adrenal hormones were examined in all groups. BMD was measured by dual-energy X-ray absorptiometry in the lumbar spine (BMD lumb) and forearm (BMDfore). RESULTS We did not confirm an increased prevalence of osteoporosis and osteopenia in patients with Addison´s disease. BMD values did not correlate with hydrocortisone (HCT) doses, HCT doses calculated on body weight and body surface area as well as with duration of substitution treatment. Patients with daily HCT doses > 25 mg had significantly lower BMD in lumbar spine compared with patients with daily HCT doses 25 mg. In study group we observed decreased levels of adrenal androgens, in women also estradiol. Decreased level of serum calcium and increased level of osteocalcin, bone alkaline phosphatase, 25- hydroxyvitamin D were present in women with Addison´s disease. RANKL/OPG ratio was higher in patients with Addison´s disease compared with controls. CONCLUSION Glucocorticoid replacement therapy is not a significant risk factor for development of osteoporosis in patients with Addison disease, because this therapy only physiologically replaces endogenous cortisol deficiency. An increased RANKL / OPG ratio may indicate a relative lack of OPG. It is possible that female patients, despite adequate substitution, have an increased bone turnover and a relatively higher risk of decrease in BMD. Potential risks are higher doses of glucocorticoid replacement therapy (HCT > 25 mg daily) and a typical steroid constellation (decreased adrenocortical androgens DHEA and DHEAS and in women also estradiol).

[1]  M. Quinkler,et al.  Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[2]  A. Frigo,et al.  Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. , 2010, European journal of endocrinology.

[3]  J. Svartberg,et al.  Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. , 2009, European journal of endocrinology.

[4]  W. Arlt.  The approach to the adult with newly diagnosed adrenal insufficiency. , 2009, The Journal of clinical endocrinology and metabolism.

[5]  C. Pariante.  The role of multi-drug resistance p-glycoprotein in glucocorticoid function: studies in animals and relevance in humans. , 2008, European journal of pharmacology.

[6]  F. Huppert,et al.  Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. , 2008, The Journal of clinical endocrinology and metabolism.

[7]  L. Saba,et al.  Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile. , 2007, The Journal of clinical endocrinology and metabolism.

[8]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[9]  R. Ho,et al.  MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. , 2006, Journal of pharmaceutical sciences.

[10]  S. Hahner,et al.  Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements , 2006, Clinical endocrinology.

[11]  S. Lightman,et al.  Why is the management of glucocorticoid deficiency still controversial: a review of the literature , 2005, Clinical endocrinology.

[12]  T. Sakaeda.  MDR1 genotype-related pharmacokinetics: fact or fiction? , 2005, Drug metabolism and pharmacokinetics.

[13]  M. Kassem,et al.  Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures , 2005, Calcified Tissue International.

[14]  H. Bozkaya,et al.  The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women. , 2004, Journal of women's health.

[15]  L. Hofbauer,et al.  Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. , 2004, JAMA.

[16]  M. Hotta,et al.  An assessment of bone mineral density in patients with Addison's disease and isolated ACTH deficiency treated with glucocorticoid. , 2004, Endocrine journal.

[17]  C. Mølgaard,et al.  Normal Bone Mineral Content in Young Adults with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency , 2004, Hormone Research in Paediatrics.

[18]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[19]  Peter W. Swaan,et al.  Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids , 2003, Pharmaceutical Research.

[20]  G. Martínez,et al.  Long‐term follow‐up of bone mineral density in Addison's disease , 2003, Clinical endocrinology.

[21]  W. Oyen,et al.  Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. , 2003, The Journal of clinical endocrinology and metabolism.

[22]  E. Husebye,et al.  Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  P. Seed,et al.  Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. , 2002, Metabolism: clinical and experimental.

[24]  S. Khosla,et al.  Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. , 2002, European journal of endocrinology.

[25]  A. Klibanski,et al.  Androgens and bone density in women with hypopituitarism. , 2002, The Journal of clinical endocrinology and metabolism.

[26]  K. Godang,et al.  Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. , 2001, European journal of endocrinology.

[27]  P J Lucassen,et al.  Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. , 2001, Endocrinology.

[28]  Y. Asano,et al.  Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  J. Jamart,et al.  [Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease]. , 2000, Annales d'endocrinologie.

[30]  D. Lacey,et al.  Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. , 1999, Endocrinology.

[31]  M. Bidlingmaier,et al.  Dehydroepiandrosterone replacement in women with adrenal insufficiency. , 1999, The New England journal of medicine.

[32]  I. Reid,et al.  Bone Mineral Density in Patients with Treated Addison’s Disease , 1999, Osteoporosis International.

[33]  J. Winter,et al.  The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. , 1997, The Journal of clinical endocrinology and metabolism.

[34]  R. Eastell,et al.  Glucocorticoid replacement therapy: are patients over treated and does it matter? , 1997, Clinical endocrinology.

[35]  R. Eastell,et al.  Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia , 1996, Clinical endocrinology.

[36]  P. V. van Rijk,et al.  Effect of Glucocorticoid Replacement Therapy on Bone Mineral Density in Patients with Addison Disease , 1994, Annals of Internal Medicine.

[37]  K. Papapietro,et al.  Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. , 1994, Bone and mineral.

[38]  E. Bonucci,et al.  Bone loss in response to long-term glucocorticoid therapy. , 1990, Bone and mineral.

[39]  J. Devogelaer,et al.  Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. , 1987, British medical journal.